Spero Therapeutics, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2018 | $-12.0M | $-12.0M | — | $614.0K |
| Jun 2018 | $-8.6M | $-8.6M | — | $661.0K |
| Sep 2018 | $-5.5M | $-5.5M | — | $705.0K |
| Dec 2018 | $-13.5M | $-13.5M | — | $769.0K |
| Mar 2019 | $-10.9M | $-11.0M | $81.0K | $933.0K |
| Jun 2019 | $-12.1M | $-12.2M | $87.0K | $933.0K |
| Sep 2019 | $-9.7M | $-9.7M | $17.0K | $981.0K |
| Dec 2019 | $-17.4M | $-17.5M | $129.0K | $929.0K |
| Mar 2020 | $-23.3M | $-23.4M | $79.0K | $1.1M |
| Jun 2020 | $-24.9M | $-24.9M | $15.0K | $1.2M |
| Sep 2020 | $-21.3M | $-21.3M | $51.0K | $1.2M |
| Dec 2020 | $-16.4M | $-16.4M | $12.0K | $1.4M |
| Mar 2021 | $-15.5M | $-15.5M | — | $2.0M |
| Jun 2021 | $-16.6M | $-16.6M | — | $2.2M |
| Sep 2021 | $-5.0M | $-5.0M | — | $2.3M |
| Dec 2021 | $-27.3M | $-27.3M | — | $2.9M |
| Mar 2022 | $-28.2M | $-28.2M | — | $3.2M |
| Jun 2022 | $-23.0M | $-23.0M | — | $1.3M |
| Sep 2022 | $-957.0K | $-957.0K | — | $2.1M |
| Dec 2022 | $44.5M | $44.5M | — | $2.5M |
| Mar 2023 | $-12.9M | $-12.9M | — | $2.2M |
| Jun 2023 | $-18.6M | $-18.6M | — | $1.9M |
| Sep 2023 | $15.9M | $15.9M | — | $1.9M |
| Dec 2023 | $-17.5M | $-17.5M | — | $2.0M |
| Mar 2024 | $5.9M | $5.9M | — | $2.0M |
| Jun 2024 | $-18.7M | $-18.7M | — | $2.1M |
| Sep 2024 | $12.8M | $12.8M | — | $2.2M |
| Dec 2024 | $-23.4M | $-23.4M | — | $1.5M |
| Mar 2025 | $-4.0M | $-4.0M | — | $1.6M |
| Jun 2025 | $-17.7M | $-17.7M | — | $714.0K |
| Sep 2025 | $17.4M | $17.4M | — | $1.0M |
| Dec 2025 | $-8.4M | $-8.4M | — | $1.0M |
| Mar 2026 | $15.9M | $15.9M | — | $1.1M |
| Jun 2026 | $-5.4M | $-5.4M | — | $822.0K |